Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia
Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-07-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849429668491427840 |
|---|---|
| author | Tracy Murphy Boyang Zhang Tong Zhang Ian King Jose-Mario Capo-Chichi Vikas Gupta Dawn Maze Caroline J. McNamara Mark D. Minden Aaron D. Schimmer Andre C. Schuh Hassan Sibai Karen W.L. Yee Andrea Arruda Zhibin Lu Dina Khalaf Chantal Rockwell Brian Leber Mitchell Sabloff Anne Tierens Tracy L. Stockley Steven M. Chan Stanley W.K. Ng Jean C.Y. Wang |
| author_facet | Tracy Murphy Boyang Zhang Tong Zhang Ian King Jose-Mario Capo-Chichi Vikas Gupta Dawn Maze Caroline J. McNamara Mark D. Minden Aaron D. Schimmer Andre C. Schuh Hassan Sibai Karen W.L. Yee Andrea Arruda Zhibin Lu Dina Khalaf Chantal Rockwell Brian Leber Mitchell Sabloff Anne Tierens Tracy L. Stockley Steven M. Chan Stanley W.K. Ng Jean C.Y. Wang |
| author_sort | Tracy Murphy |
| collection | DOAJ |
| description |
Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients. Each patient’s score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs 94% after induction, P |
| format | Article |
| id | doaj-art-9203b3d2b89d41a4bc725e7403fcf64e |
| institution | Kabale University |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-9203b3d2b89d41a4bc725e7403fcf64e2025-08-20T03:28:17ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-07-01999110.3324/haematol.2025.287777Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemiaTracy Murphy0Boyang Zhang1Tong Zhang2Ian King3Jose-Mario Capo-Chichi4Vikas Gupta5Dawn Maze6Caroline J. McNamara7Mark D. Minden8Aaron D. Schimmer9Andre C. Schuh10Hassan Sibai11Karen W.L. Yee12Andrea Arruda13Zhibin Lu14Dina Khalaf15Chantal Rockwell16Brian Leber17Mitchell Sabloff18Anne Tierens19Tracy L. Stockley20Steven M. Chan21Stanley W.K. Ng22Jean C.Y. Wang23Princess Margaret Cancer Centre, University Health Network, Toronto, ONDepartment of Biological Chemistry, School of Medicine, University of California, Irvine (UCI), Irvine, CaliforniaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ONDivision of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ONJuravinski Cancer Centre, Hamilton, ONThe Ottawa Blood Disease Centre, The Ottawa Hospital, Ottawa, ONJuravinski Cancer Centre, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ONThe Ottawa Blood Disease Centre, The Ottawa Hospital, Ottawa, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ONPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Biological Chemistry, School of Medicine, University of California, Irvine (UCI), Irvine, CaliforniaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Toronto, Ontario M<sup>5</sup>G 2M9, Canada; Department of Medicine, University of Toronto, Toronto, Ontario M5G 1A1 Acute myeloid leukemia (AML) patients exhibit diverse molecular and cytogenetic changes with heterogeneous outcomes. The functionally-derived LSC17 gene expression score has demonstrated strong prognostic significance in retrospective analyses of adult and pediatric AML cohorts, where above-median scores are associated with worse outcomes compared to below-median scores in intensively-treated patients. Here we used a laboratory-developed clinically-validated NanoStringbased LSC17 assay to test the prognostic value of the LSC17 score in a prospective multicentre study of 276 newly-diagnosed AML patients. Each patient’s score was classified as high or low by comparison to a previously-established reference score. In the entire cohort, a high LSC17 score was associated with poor risk features, including advanced age and unfavorable genetic mutations. In the subset of 190 patients treated intensively, a high LSC17 score was associated with lower remission rates (63% vs 94% after induction, Phttps://haematologica.org/article/view/12171 |
| spellingShingle | Tracy Murphy Boyang Zhang Tong Zhang Ian King Jose-Mario Capo-Chichi Vikas Gupta Dawn Maze Caroline J. McNamara Mark D. Minden Aaron D. Schimmer Andre C. Schuh Hassan Sibai Karen W.L. Yee Andrea Arruda Zhibin Lu Dina Khalaf Chantal Rockwell Brian Leber Mitchell Sabloff Anne Tierens Tracy L. Stockley Steven M. Chan Stanley W.K. Ng Jean C.Y. Wang Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia Haematologica |
| title | Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| title_full | Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| title_fullStr | Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| title_full_unstemmed | Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| title_short | Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| title_sort | real world validation study of the lsc17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia |
| url | https://haematologica.org/article/view/12171 |
| work_keys_str_mv | AT tracymurphy realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT boyangzhang realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT tongzhang realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT ianking realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT josemariocapochichi realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT vikasgupta realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT dawnmaze realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT carolinejmcnamara realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT markdminden realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT aarondschimmer realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT andrecschuh realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT hassansibai realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT karenwlyee realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT andreaarruda realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT zhibinlu realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT dinakhalaf realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT chantalrockwell realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT brianleber realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT mitchellsabloff realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT annetierens realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT tracylstockley realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT stevenmchan realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT stanleywkng realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia AT jeancywang realworldvalidationstudyofthelsc17scoreforriskpredictioninpatientswithnewlydiagnosedacutemyeloidleukemia |